Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 4 EP applications Daniela Deriu has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after February 23, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11746252

ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/32
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP11718982

COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN -RELATED PROTEIN 6 (LRP6) ANTIBODIES

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/46, C12N 15/113
Applicant:
Novartis AG
Agent:
Cameron Marshall, Carpmaels & Ransford LLP
Agent:
Daniela Deriu, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP11723308

COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/46, C12N 15/113
Applicant:
Novartis AG
Agent:
Cameron Marshall, Carpmaels & Ransford LLP
Agent:
Daniela Deriu, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11785007

METHODS OF TREATING FGF21-ASSOCIATED DISORDERS

IPC classification:
C07K 14/50
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS

Please Sign in to use this feature